In the Special Report by Lynn Jeanette Savic, Julius Chapiro1, Gregor Duwe & Jean-François Geschwind, titled ‘Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?’, which appeared in the January 2016 issue of Hepatic Oncology (Hepatic Oncology 3[1], 19–28 [2016]), the Financial & competing interests disclosure should have detailed NIH funding as follows:
‘JF Geschwind reports grants from National Institutes of Health (NIH/NCI R01 CA160771, P30 CA0069730).’
The authors and editors of Hepatic Oncology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.